Cancer is a complex systemic disease, with accompanying secondary effects that can result in debilitating effects on the human body. Cancer-associated skeletal muscle weakening or loss, also called “cancer cachexia,” is a prevalent and serious condition responsible for 20%–30% of the deaths in affected cancer patients. In current treatments for cancer cachexia, there are limitations in efficacy levels and significant side effects.

Published in Molecular Therapy, the study found that drug-loaded RBCEVs inhibited  could increase muscle growth and suppress cancer cachexia. Compared to the delivery of a single RNA drug, muscle growth was observed to be further enhanced when two RNA drugs targeting two different genes implicated in cancer cachexia were loaded into the same RBCEVs. Importantly, repeated administrations with RBCEVs did not induce toxicity or inflammatory reactions, which is a prerequisite for clinical trials on humans.

“There is a lot of potential in using RNA-based drugs for conditions that are difficult to treat, but the delivery has always been tricky. From our previous and current studies, we have found that the RBCEV delivery platform can help to overcome some of the long-standing technical challenges in the field,” said Assistant Professor Minh Le from WisDM and the Department of Pharmacology at NUS Medicine, who led the study.

Professor Ng Shyh-Chang, Principal Investigator for the State Key Laboratory of Stem Cell and Reproductive Biology at the CAS Institute of Zoology, who co-directed the study, added, “Building on previous target discovery work, this is one of the first studies to leverage RNA therapies to treat cancer cachexia. This could lead to the use EV-based gene therapies to address unmet needs in cachexia and sarcopenia.”

The team has plans for further collaborations to test the use of RBCEV-delivered therapeutics against other targets in the muscles. At the same time, they have been working on applying RBCEVs to the treatment of different cancers, cardiovascular diseases, and COVID-19. Accumulating data from their studies, the RBCEV has shown to be a robust, safe and versatile platform.

As the collective understanding of RBCEV biology and related technologies continue to mature, the RBCEV platform is well-positioned for clinical translation to provide safer and more efficacious treatment options for muscle degenerative conditions as well as other challenging diseases.

News

Aging Spreads Through the Bloodstream

Summary: New research reveals that aging isn’t just a local cellular process—it can spread throughout the body via the bloodstream. A redox-sensitive protein called ReHMGB1, secreted by senescent cells, was found to trigger aging features [...]

Nanomaterials in Ophthalmology: A Review

Eye diseases are becoming more common. In 2020, over 250 million people had mild vision problems, and 295 million experienced moderate to severe ocular conditions. In response, researchers are turning to nanotechnology and nanomaterials—tools that are transforming [...]